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Abstract: Moxifloxacin hydrochloride ophthalmic solution 0.5% (Vigamox®) is the 
ocular formulation/adaptation of moxifloxacin. Moxifloxacin is a broad spectrum 
8-methoxyﬂ  uoroquinolone which terminates bacterial growth by binding to DNA gyrase 
(topoisomerase II) and topoisomerase IV, essential bacterial enzymes involved in the 
replication, translation, repair and recombination of deoxyribonucleic acid. Afﬁ  nity for 
both enzymes improves potency and reduces the probability of selecting resistant bacterial 
subpopulations. Vigamox is a bactericidal, concentration dependent, anti-infective. It is 
preservative free, and well tolerated with minimal ocular side effects. It provides increased 
penetration into ocular tissues and ﬂ  uids with improved activity against Streptococci and 
Staphylococci species and moderate to excellent activity against clinically relevant, gram-
negative ocular pathogens.
Keywords: moxifloxacin, vigamox, pharmacodynamic indices, minimal inhibitory 
concentrations
Introduction
Moxiﬂ  oxacin hydrochloride ophthalmic solution 0.5% is the ocular formulation/adap-
tation of moxiﬂ  oxacin, an 8-methoxyﬂ  uoroquinolone, broad spectrum, anti-infective. 
It was introduced in 2003 as Vigamox® (Alcon Laboratories, Inc, Fort Worth, TX, 
USA) for the treatment of susceptible microorganisms recovered from patients with 
bacterial conjunctivitis. It is used more frequently off label for treatment of keratitis 
and as a prophylaxis agent in cataract and refractive surgeries (Vigamox 2004; Alfonso 
and Crider 2005; Schlech and Alfonso 2005).
It is an isotonic, preservative free, solution with a near neutral pH of 6.8. The 
formula of Vigamox includes 5 mg/mL (0.5%) of moxiﬂ  oxacin, boric acid, and puri-
ﬁ  ed water. Lack of the preservative BAK (benzalkonium chloride) makes it unique 
among current topical antibiotics licensed for use. Vigamox is currently available in 
more than 40 countries. Moxiﬂ  oxacin hydrochloride ophthalmic solution 0.5%, under 
the trade name Vegamox®, was introduced into Japan in 2006, with approval for the 
treatment of bacterial conjunctivitis, keratitis and surgical prophylaxis.
Chemistry
Figure 1 shows the basic molecule and Figure 2 the moxiﬂ  oxacin molecule. Table 1 
shows the impact of core modiﬁ  cations.
Moxiﬂ  oxacin
Moxiﬂ  oxacin is a broad spectrum, 8-methoxy ﬂ  uoroquinolone with improved activ-
ity against Streptococci and Staphylococci and moderate to excellent activity against 
clinically relevant, gram negative ocular pathogens (Smith et al 2001; Keating and 
Scott 2004).Clinical Ophthalmology 2008:2(1) 78
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Modiﬁ  cation of the parent molecule’s core 4-quinolone 
core, at positions 1, 5, 7, and 8 has engineered novel ﬂ  uoro-
quinolones with enhanced antimicrobial activity, safety and 
tolerability (Keating and Scott 2004). Substitutions at the N-1 
nitrogen atoms are critical for the spectrum of activity and 
potency of the molecule. The N-1 cyclopropyl substitution in 
moxiﬂ  oxacin confers increased activity against gram-positive 
and anaerobic isolates. Substitutions at the C-5 position also 
impact the in vitro activity against gram-positive isolates; the 
larger the molecule the greater the gram positive potency. 
Addition of a bulky C-7 (diazabicyclononyl ring) side chain 
and a methoxy group at the C-8 position reduces the poten-
tial for selection of resistant bacterial subpopulations and 
increase the binding/blocking afﬁ  nity for DNA gyrase and 
topoisomerase IV, essential bacterial enzymes (Domagala 
1994; Ball et al 1998; Appelbaum and Hunter 2000; Peterson 
2001; Zhanel et al 2002; Caeiro and Iannini 2003; Saravolatz 
and Leggett 2003)
These modifications were incorporated to meet the 
challenge of emerging resistance in the older ﬂ  uoroquinolones 
among ocular and nonocular isolates (Blondeau 1999; 
Chaudhry et al 1999; Goldstein et al 1999; Alexandrakis 
et al 2000; Zhanel and Noreddin 2001; Mather et al 2002; 
Hwang 2004; Mah 2004; Marangon et al 2004; Van Bambeke 
et al 2005).
Mechanism of action
Moxiﬂ  oxacin is a bactericidal, concentration dependent, 
anti-infective. It interferes with bacterial survival by bind-
ing to DNA gyrase (topoisomerase II) and topoisomerase 
IV, essential bacterial enzymes involved in the replication, 
translation, repair and recombination of deoxyribonucleic 
acid. DNA gyrase is encoded by the genes gyra A and gyr 
B, while topoisomerase IV is encoded by Par C (grl A) and 
pare (grl B). Inhibition of either enzyme leads to bacteria 
death (Zhanel and Noreddin 2001; Hwang 2004; Mah 2004; 
Van Bambeke et al 2005).
All ﬂ  uoroquinolones bind to DNA gyrase and topoi-
somerase enzymes in susceptible organisms. The afﬁ  nity 
or strength of the attachment varies; dependent on the class 
of ﬂ  uoroquinolone and the bacteria species. Moxiﬂ  oxacin 
binds strongly to both DNA gyrase and topoisomerase, 
but demonstrates preferential binding to DNA gyrase in 
gram-negative pathogens and Streptococcus pneumoniae. 
There is controversy as to the preferential target in the 
staphylococci. Preferential of dual targeting conﬁ  rmation 
is dependent on methods used to evaluate the targets, and 
wild type strains employed to generate the mutants (Hooper 
2001a; Oliphant and Green 2002; Ball et al 2004; Keating 
and Scott 2004).
Studies conﬁ  rmed that for the older ﬂ  uoroquinolones such 
as ciproﬂ  oxacin, topoisomerase IV is the preferred target in 
gram positive bacteria (Ball et al 1998; Dalhoff and Schmitz 
2003; Drlica and Malik 2003; Zhanel et al 2006). In vitro 
studies supporting the dual activity of moxiﬂ  oxacin have 
been mixed. Takei and colleagues using MIC ratios; classiﬁ  ed 
moxiﬂ  oxacin as a class three quinolone exhibiting dual activ-
ity against the two enzymes in Staphylococcus aureus (Takei, 
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Figure 1 Basic 4-quinolone structure (adapted from Domagala 1994).
Table 1 Impact of core modiﬁ  cation and potency to the ﬂ  uoroquinolones
Substitution area  Structure/side effects relationship
R1   This area is part of the enzyme-DNA binding complex-inappropriate stereochemistry inhibits 
activity. A cyclopyl substitution here increases topoisomerase binding.
R2  Area closes to the gyrase binding site: bulky side chains lowers potency
R3-R4  These two groups interact with cleaved or damage DNA; no good substitutions/alternatives have
 been  found
R-5  Substitutions here affects topoisomerase afﬁ  nity,   A NH2 or CH3 group adds gram-positive activity
R-6  Affects potency; NH2 or H possible, Interactions of (R6+7+8) are key
R-7  Interacts with DNA gyrase. Bulky side chain here impedes efﬂ  ux; increases gram positive activity
R-8  Affects target afﬁ  nity.   A CH3 or OCH3 increases afﬁ  nity against anaerobes
Adapted from Domagala (1994), Peterson (2001).Clinical Ophthalmology 2008:2(1) 79
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Fukuda et al 2001). Topoisomerase IV was identiﬁ  ed as the 
preferential target, with puriﬁ  ed S. aureus DNA gyrase and 
topoisomerase IV enzymes by Ince and colleagues (Ince et al 
2003). Griggs and co-workers (Griggs et al 2003) selected 
mutants with preferred afﬁ  nity for DNA gyrase.
Exposure to ﬂ  uoroquinolones may select single step 
mutants and or bacterial populations with increased 
tolerance or resistance. Mechanisms of resistance to the 
ﬂ  uoroquinolones include subpopulations (mutants) with 
1) mutations in DNA gyrase and or topoisomerase genes 
that alter/reduce the binding afﬁ  nity of the enzymes, 2) gene 
mutations that block drug entry, 3) presence of an efﬂ  ux 
pump that reduces drug accumulation and 4) unique genes 
that confer speciﬁ  c resistance against S. aureus (Zhanel et al 
2002; Wise 2003; Mah 2004; Jacoby 2005; Van Bambeke 
et al 2005). Rare or emerging resistant mechanisms 
include 1) the presence of plasmids that protect cells from 
the lethal effects of the ﬂ  uoroquinolones and 2) acquisition 
of a ﬂ  uoroquinolone modifying enzyme (Robicsek et al 
2006; Robicsek et al 2006).
Low level ﬂ  uoroquinolone resistant populations usually 
contain a single mutation in DNA gyrase or topoisomerase 
IV. The preferred or primary target varies with the bacteria 
species and the ﬂ  uoroquinolone. Key mutations usually occur 
in a unique region known as the quinolone resistant determin-
ing region (QRDR) of either DNA gyrase or topoisomerase 
IV. Secondary mutations may also occur in genes outside of 
these regions, in genes encoding efﬂ  ux pumps, membrane 
permeability and cell transport. High level resistant isolates 
contain multiple gene mutations both in primary and in 
secondary targets. In areas with preexisting low levels of 
ﬂ  uroquinolone resistance, exposure to suboptimal levels of 
the new ﬂ  uoroquinolones will lead to rapid progression to 
double mutants and high level resistance (Hooper 2001b; 
Smith et al 2001; Zhanel et al 2002; Hwang 2004; Miller 
and Alfonso 2004).
Figure 3 highlights the evolution of ﬂ  uoroquinolones 
resistance among ocular isolates recovered from postop-
erative endophthalmitis cases from one region (Miller et al 
2006). At base line (1990–1994), low level resistance to 
ciproﬂ  oxacin (10.3%) was evident, with no documented 
resistance to levoﬂ  oxacin, gatiﬂ  oxacin, or moxiﬂ  oxacin. 
Emergence of multistep mutants or subpopulations resistant 
to levoﬂ  oxacin and the 8 methoxy ﬂ  uoroquinolones were 
steeper and almost 3 times higher compared to ciproﬂ  oxa-
cin during the initialﬁ  ve years following ciproﬂ  oxacin’s 
introduction. Increasing resistance to ciproﬂ  oxacin and 
levoﬂ  oxacin doubled in the last 5 years. Resistant populations 
increased by 8.9% for gatiﬂ  oxacin and 5.1% for moxiﬂ  oxacin 
during that same time period.
Spectrum of activity
In vitro studies comparing minimal inhibitory concentra-
tions (MICs) from the United States, Asia and Europe have 
documented the in vitro efﬁ  cacy of moxiﬂ  oxacin against a 
broad array of ocular and nonocular pathogens (Blondeau 
1999; Krasemann, Meyer et al 2001; Zhanel, Ennis et al 
2002; Caeiro and Iannini 2003; Dalhoff and Schmitz 2003; 
Hwang 2004; Keating and Scott 2004; Mah 2004). Emerging 
trends indicate enhanced activity and excellent coverage for 
S. pneumoniae, Haemophilus inﬂ  uenzae, and methicillin sus-
ceptibile staphylococci compared to older ﬂ  uoroquinolones. 
There was near equivocal coverage for Enterobacteriaceae, 
Pseudomonas aeruginosa, and other nonfermenters, but 
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suboptimal coverage for methicillin resistant staphylococci 
and enterococci, Table 2.
Greater than 10% resistance for moxiﬂ  oxacin and or 
gatiﬂ  oxacin was documented for several ocular pathogens, 
including S. pneumoniae (11.9%), methicillin resistant 
S. aureus (95% USA, 23.3% Taiwan, methicillin resistant 
Staphylococcus epidermidis (69% USA, 40% Taiwan) and 
P. aeruginosa (18.3% Taiwan).
Currently, there are few large, credible studies evaluat-
ing in vitro activity of moxiﬂ  oxacin against new and older 
ﬂ  uoroquinolones for common ocular pathogens. Many are 
hampered by low numbers of isolates (less than 30 per spe-
cies), incomplete panel of challenge, comparative antibiotics 
or spectrum of pathogens and use conﬂ  icting or outdated 
interpretation standards.
Table 3 compares minimal inhibitory concentrations 
needed to inhibit 90% of pathogens (MIC90s) for select ocular 
pathogens from North and South America for ciproﬂ  oxacin, 
gatiﬂ  oxacin, and moxiﬂ  oxacin. Results are impacted by 
methodology, isolate mix, testing period and interpretation 
standard applied. Minimal inhibitory concentrations against 
relevant ocular pathogens indicated that the 8-methoxy 
ﬂ  uoroquinolones have improved efﬁ  cacy against common 
ocular pathogens compared to ciproﬂ  oxacin. MIC90s were 
2–4 times lower for moxiﬂ  oxacin versus ciproﬂ  oxacin and 
lower than or equivocal to gatiﬂ  oxacin among important 
ocular pathogens. Percent susceptible ranged from 24% 
(methicillin-resistant staphylococci) to 100% (S. pneumoniae) 
(Mather et al 2002; Kowalski et al 2003; Kowalski et al 2005; 
Stroman et al 2005; Oliveira et al 2007). Isolates resistant to 
ciproﬂ  oxacin were in general also resistant to moxiﬂ  oxacin 
and gatiﬂ  oxacin.
Resistance patterns to the fluoroquinolones vary by 
region, country, and ocular site. Studies comparing endemic 
background ciprofloxacin resistance demonstrated wide 
variation across regions in Europe, and North and South 
America (Table 4). Emerging resistant rates to moxiﬂ  oxacin 
and gatiﬂ  oxacin correlated with background ciproﬂ  oxacin 
resistant rates. Regions with the highest endemic resistance 
also reported the highest resistant rates to moxiﬂ  oxacin and 
gatiﬂ  oxacin (Mather et al 2002; Kowalski et al 2003; Kowalski 
et al 2005; Oliveira et al 2007) (Miller 2006, unpublished).
Other microbial pathogens considered susceptible to 
moxiﬂ  oxacin include Chlamydia pneumoniae, Chlamydia 
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Figure 3 Evolution of ﬂ  uoroquinolone resistance among coagulase negative staphylococci recovered from patients with post operative endophthalmitis (N = 78 isolates) 
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trachomatis, Legionella pneumoniae and the some 
Mycobacteria species (Vigamox 2004).
Treatment of nontuberculosis with the 8-methoxyﬂ  uoro-
quinolones has been mixed. In a review of the early literature, 
Abshire and colleagues (Alcon Laboratories) offered data 
to support the use of moxiﬂ  oxacin in the prevention and 
treatment on mycobacterial keratitis (Abshire et al 2004). 
Several case and series report successful treatment out-
comes with the 8 methoxyﬂ  uoroquinolones as adjunctive 
therapy (Lee et al 2005; Chang and Welty 2006 p 272; John 
Table 2 Comparative in vitro susceptibility of ciproﬂ  oxacin, gatiﬂ  oxacin, and moxiﬂ  oxacin against select nonocular pathogens
Country  Time period  Pathogen  N  MIC 90 μg/mL     Reference
         Moxiﬂ  oxacin  Gatiﬂ  oxacin  Ciproﬂ  oxacin 
Canada Collected  prior
 to  1999 
   S. aureus        
   MSSA  365 0.125  (S)a 0.25  (S)  NDb  Blondeau et al 2000
    MRSA  42  2 (R )  4 (R)  ND 
   S. pneumoniae  399  0.25 (S)  0.25–0.5 (S)  ND 
   H. inﬂ  uenzae  199  0.063 (S)  0.016 (S)  0.031 (S) 
   P. aeruginosa  1472  16  8 (R)  4 (R ) 
   M. catarrhalis  337  0.063 (S)  0.031 (S)  0.031 (S) 
   P. mirabilis  30  0.5  0.25 (S)  0.031 (S)
USA 1999–2001  S. pneumoniae  3304  0.25 (S)  0.5 (S)  2  Jones et al 2003
   H. inﬂ  uenzae  3371  0.03 (S)  0.03 (S)  0.03 (S) 
   M. catarrhalis  1656  0.06 (S)  0.03 (S)  0.03 (S) 
USA  April–December  MSSA  34  0.06 (S)    1 (S)  Fass 1997
 1996
   MRSA  20  4  (R)    32 (R) 
    MSSE  23  0.12 (S)    0.5 (S) 
   MRSE  29  2  (R)    32 (R) 
   S. pneumoniae 50  0.25  (S)    1 
   H. inﬂ  uenzae  45  0.03 (S)    0.015 (S) 
   P. mirabilis 33  2    0.25  (S) 
   P. aeruginosa 26  = 32  32 (R) 
Taiwan 1998–1999  MSSA  58  0.06  (S)    0.5  (S)  Sheng  Wang-Huei,
              et al 2001
    MRSA  60  2 (R)    16 (R) 
   MSSE  58  0.12  (S)    1  (S) 
    MRSE  60  8 (R)    128 (R) 
   S. pneumoniae 42  4  (R)    128 
   P. aeruginosa 60  2    0.25  (S) 
Europe (14),   April 1997–  MSSA  434  0.06 (S)  0.12 (S)  0.5 (S)  Milatovic et al 2000
Israel (1),  February 1999
South America (3)
    MRSA  457  4 (R)  4 (R)  16 (R) 
    MSSE  214  1 (I)  2 (R)  16 (R) 
    MRSE  436  2 (R)  2 (R)  16 (R) 
    CoNS, other  111  8 (R)  8 (R)  16 (R) 
   S. pneumoniae  427  .25 (S)  .5 (S)  2 
   S. viridans group 97  0.25  0.5  (S)  4 
   H. inﬂ  uenzae  224  0.03 (S)  .015 (S)  0.15 (S) 
   P. aeruginosa 615  16  16  16 (R) 
   P. mirabilis 319  16  4(R)  4  (R) 
   S. marcescens  211  4  2 (S)  2 (I) 
aInterpretations were in accordance with the Clinical and Laboratory Standard Institute (CLSI) Performance for Antimicrobial Susceptibility Testing; Seventeenth Informational 
Informational Supplement. M100-S17. S, sensitive, I, intermediate, R, resistant.
bND = not done. No CLSI standards for S. pneumoniae or S. viridans group and ciproﬂ  oxacin. No CLSI standards for gatiﬂ  oxacin and moxiﬂ  oxacin and P. aeruginosa. No CLSI 
standards for moxiﬂ  oxacin S. marcescens, S. viridans group, and P. mirabilis.
Abbreviations: MIC90, concentration that inhibits 90% of isolates tested; MSSA, methicillin sensitive Staphylococcus aureus; MRSA, methicillin resistant Staphylococcus aureus; MSSE, 
methicillin sensitive Staphylococcus epidermidis; MRSE, methicillin resistant Staphylococcus epidermidis; P. aeruginosa, Pseudomonas aeruginosa, M. catarrhalis, Moraxella catarrhalis; S. 
pneumoniae, Streptococcus pneumoniae; H. inﬂ  uenzae; Haemophilus inﬂ  uenzae; P. mirabilis, Proteus mirabilis; S. aureus, Staphylococcus aureus; S. viridans group; Streptococcus viridans 
group; CoNS other, coagulase negative staphylococci other than S. epidermidis; S. marcescens, Serratia marcescens.Clinical Ophthalmology 2008:2(1) 82
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and Velotta 2005 p 461). Others have reported therapeutic 
failures with these drugs (Hoﬂ  ing-Lima et al 2005; Moshirfar 
et al 2007).
The majority of the mycobacterial keratitis cases have 
been reported following outbreaks (Freitaset al 2003; Karp 
et al 2003; Winthrop et al 2003; John and Velotta 2005). 
Increased awareness, control measures and modiﬁ  ed surgical 
techniques have reduced the frequencies of mycobacterial 
infections in the United States. The current recommendation 
for treatment of mycobacterial keratitis is alternative treatment 
with amikacin and one of the 8-methoxyﬂ  uoroquinolones 
(Donnenfeld et al 2005).
Case reports and series from other ocular sites have been 
rare (Gupta et al 2003; Wilhelmus 2003; Nielsen et al 2004; 
Table 3 Comparative MIC90s for moxiﬂ  oxacin, gatiﬂ  oxacin, and ciproﬂ  oxacin against select ocular pathogens
  Type  Ocular source  Number MIC 90 μg/mL Time  Period  Reference
       Moxiﬂ  oxacin  Gatiﬂ  oxacin  Ciproﬂ  oxacin    
S. aureus    Cornea         
 FQS   25  0.047  (S)a  0.22 (S)  0.5 (S)  1993–2003  Kowalski et al 2003
  FQR    25  4 (R)  12 (R)  128 (R)   
  FQS  Conjunctiva  20  0.094 (S)  0.125 (S)  0.5 (S)  1998–2002  Kowalski 
    isolates          et  al  2005
 FQR    20  6.0  (R)  64  (R)  32 (R)
  NOS  All ocular  21  0.25 (S)  0.125 (S)  0.25 (S)  2002–2004  Oliveira 
              et  al  2007
  MSSA  All ocular  53  1.5 (R)  1.5 (R)  32 (R)  2001–2006  Miller 2006,
              unpublished
  MRSA    39  32 (R)  32 (R)  32 (R)   
Coagulase      cornea         
negative 
Staphylococci FQS
      10  0.125 (S)  0.19 (S)  0.3/8 (S)  1993–2002  Kowalski 
              et  al  2003
  FQR    10  3 (R )  3 (R)  64 (R)   
  FQS  Intraocular   10  0.05 (S)  0.09 (S)  0.13 (S)  1993–2000  Mather et al 2002
   ﬂ  uids
  FQR    10  2.5 (R)  2 (R)  2.0 (R)   
Coagulase   NOS  all ocular  66  32 (R)  32 (R)  32 (R)  2001–2006  Miller 2006,
Negative                unpublished
Staphylococci,             
Coagulase     All ocular          2002–2004  Oliveira 
Negative              et  al  2007
Staphylococci,
  FQS    57  0.75 (I)  1 (I)  2 (I)   
  FQR    21  3 (R)  2 (R)  32 (R)   
S. pneumoniae    Cornea  20  0.19 (S)  0.25 (S)  2 (I)  1993–2002  Kowalski 2003
    Conjunctiva  20  0.09 (S)  0.19 (S)  0.75 (S)  1998–2002  Kowalski 2005
   Intraocular  ﬂ  uids  10  0.09 (S)  0.22 (S)  0.75 (S)  1993–2000  Mather et al 2002
    All ocular  20  0.19 (S)  0.19 (S)  3 (R)  2001–2006  Miller 2006,
              unpublished
    All ocular  16  0.12 (S)  0.19 (S)  1 (S)  2002–2004  Oliveira et al 2007
P. aeruginosa  FQS  Cornea  25  0.75  0.38  0.094 (S)  1993–2002  Kowalski et al 2003
   All  ocular  40  32  32  32 (R)  2001–2006  Miller 2006,
              unpublished
    All ocular  23  2  1  0.25 (S)  2002–2004  Olivera et al 2007
H. inﬂ  uenzae    Cornea  10  0.19 (S0)  0.06 (S)  0.03 (S)  1993–2002  Kowalski et al 2003
    Conjunctiva  20  0.12 (S)  0.25 (S)  1.0 (S)  1998–2002  Kowlaski et al 2005
    All ocular  21  0.5 (S)  0.32 (S)  0.19 (S)  2002–2004  Oliveira et al 2007
aInterpretations were in accordance with the Clinical and Laboratory Standard Institute (CLSI) Performance for Antimicrobial Susceptibility Testing; Seventeenth Informa-
tional Informational Supplement. M100-S17. S, sensitive; I, intermediate; R, resistant.
bNo CLSI standards for S. pneumoniae and ciproﬂ  oxacin. No CLSI standards for gatiﬂ  oxacin and moxiﬂ  oxacin and P. aeruginosa.
Abbreviations: MSSA, methicillin sensitive Staphylococcus aureus; MRSA, methicillin resistant Staphylococcus aureus; MIC90, concentration that inhibits 90% of isolates tested; FQS, 
ﬂ  uoroquinolone sensitive; FQR, ﬂ  uroquinolone resistant; NOS, Staphylococcus aureus, not otherwise speciﬁ  ed or Coagulase negative staphylococci not otherwise speciﬁ  ed.Clinical Ophthalmology 2008:2(1) 83
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Spencer et al 2005; Matieli et al 2006). Treatment strategies 
include amikacin and clarithromycin (Wilhelmus 2003).
The antifungal activities of the 8-methoxyﬂ  uoroquino-
lones have been investigated. There is both in vitro and in 
vivo evidence for some efﬁ  cacy of the 8 methoyl ﬂ  uoroqui-
nolones to reduce fungal loads in the lab and for patients with 
contact lens associated fungal keratitis. Additional studies 
need to be done (Ozdek et al 2006; Munir et al 2007)
Pharmacokinetics
Direct application of topical antimicrobial to conjunctival 
and corneal tissues can initially provide very high local and 
aqueous chamber concentrations. Final or sustained concen-
trations are altered by rapid tear ﬁ  lm dissipation, underlying 
tissue health and dosing frequency (Robertson et al 2005; 
Stroman et al 2005).
Penetration of moxifoxacin has been studied in ocular 
tissues and ﬂ  uids in both humans and animals. Human studies 
have revealed wide variation in drug concentrations. Recorded 
concentrations are impacted by route of administration, 
dosing frequency, site of infection, presence or absence of 
epithelial defect and underlying disease. The recommended 
dosing frequency for the treatment of bacterial conjunctivitis 
is one drop 3 times a day for 5 days. (Vigamox 2004; 
Alfonso and Crider 2005; Robertson et al 2005; Stroman 
et al 2005)
In general, moxiﬂ  oxacin’s high concentration formula-
tion, enhanced bioavailability, and solubility have allowed 
for levels 2- to 4-fold higher ocular tissues levels than 
gatiﬂ  oxacin (Zymar®, Allergan, Irvine CA), ciproﬂ  oxacin 
(Ciloxacin®, Alcon, Ft. Worth, TX), levoﬂ  oxacin (Quixin®, 
Vistakon Pharmaceuticals, USA), or oﬂ  oxacin (Ocuﬂ  ox®, 
Allergan, Irvine, CA) (Cekic et al 1999a; Cekic et al 1999b; 
Garcia-Saenz et al 2001; Smith et al 2001; Donnenfeld et al 
2004; Hwang 2004; Mah 2004; Koch et al 2005; Robertson 
et al 2005; Chang Lin and Welty 2006; O’Brien 2006)
Table 5 summarizes studies evaluating the penetration 
of moxiﬂ  oxacin, gatiﬂ  oxacin and ciproﬂ  oxacin into the 
aqueous and vitreous chambers by topical and oral routes of 
administration. Topical dosing protocols that mimic pre and 
post dosing frequencies for cataract and refractive surgeries 
of 4 times a day, pulsing dosing or a combination of the 
two, report concentration levels in the aqueous chamber that 
ranged from 0.38 ± 0.32 μg/mL to 2.28 ± 1.23 μg/mL.
Resultant concentration in the vitreous ranged from 
0.011 ± 0.008 μg/mL to 0.11 ± 0.05 μg/mL. Vitreal 
concentrations were 20- to 40-fold lower than those obtained 
in the aqueous. (Donnenfeld et al 2004; Hariprasad et al 
2005; Hariprasad et al 2005; Katz et al 2005; Kim et al 2005a; 
Kim et al 2005b; Solomon et al 2005; Costello et al 2006; 
McCulley et al 2006; Ong-Tone 2007). Concentration levels 
in the aqueous and the vitreous were usually 2-fold higher for 
moxiﬂ  oxacin compared to gatifoxacin or ciloxacin.
Oral administration of 400–800 mg of moxiﬂ  oxacin 
ranged from 0.21 ± 0.21 μg/mL to 2.33 μg/mL ± 0.85 
and produced concentrations that were comparable to 
topical administration in the aqueous chamber. Drug levels 
were negligible in the vitreous (Garcia-Saenz et al 2001; 
Kampougeris et al 2005; Hariprasad et al 2006; Vedantham 
et al 2006; Fuller et al 2007; Walter et al 2007).
Pharmacodynamics
The therapeutic success or potency of an antibacterial 
agent is a complex interrelationship between drug and 
its ability to reach the target site (pharmacokinetics), the 
microbial pathogen and susceptibility to the selective drug 
Table 4 Regional and geographic variation in endemic ﬂ  uoroquinolone resistance (%) among ocular pathogens
Region Fluoroquinolone        Reference
 Ciproﬂ  oxacin  Gatiﬂ  oxacin  Moxiﬂ  oxacin  Number of Isolates  Time Period 
Europe 12.4  5.5  ND  532  July 2001–Dec 2002  Morrissey et al 2004
France 12.4  5.6  ND     
Germany 4.6  1.5 ND     
Italy 19.9  4.6  ND     
Spain 15.9  9.8  ND     
Sweden 2.0 0  ND     
UK 8.3  8.3  ND     
USA (Northeast)  28.3  13.7  20  350  1993–2005  Mather et al 2002;
             Kowlaski et al 2003;
             Kowalski et al 2005
USA (South Florida)  30.1  16.7  23.3  431  2000–2006  Miller 2006 (unpublished)
Brazil  14.2  11.9  11.9  183  2002–2004  Oliveira et al 2007
ND=Not done.Clinical Ophthalmology 2008:2(1) 84
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(pharmacodynamics), and the underlying immune status of 
the patient (Figure 4).
Pharmacokinetics is the dispersion and metabolism 
of the drug in the body. It is deﬁ  ned by the absorption, 
distribution, dosage and protein binding characteristics of 
the drug, which may vary among individual drugs in a class. 
Pharmacodynamics deﬁ  nes the impact of the antimicrobial 
agent on the infecting microorganism. It is characterized by 
the bacterial species, mechanism of microbial resistance, 
growth phase, infecting inoculum, degree of kill, time kill 
Table 5 Penetration studies of moxiﬂ  oxacin and comparators into aqueous and vitreous humor
Route of  Dosing  Dosage  Moxiﬂ  oxacin    Gatiﬂ  oxacin  Ciproﬂ  oxacin  Reference
Administration     Aqueous Vitreous Aqueous    Vitreous Aqueous Vitreous
    ( μg/mL) (μg/mL) (μg/mL) (μg/mL) (μg/mL) (μg/mL)
Topical  1 drop/2 hours × 3  43  2.28 ± 0.11  ±  ND ND ND ND  Hariprasad
  days  drops  1.23  0.05       et  al  2005
  1 drop/6 hours × 22  0.88  ± 0.06  ±  ND ND ND ND  Hariprasad
  3 days    0.88  0.06          et al 2005
  1 drop/10 min  4 drops  1.80 ±   0.48  ±        Kim et al
  prior to surgery    1.25    0.34        2005
 4 ×/day × 3 days  15  1.31 ±   0.63  ±   0.15  ±   Solomon
  plus 3 drops   drops  0.46    0.30    0.11    et al 2005
  1 hour prior to               
  surgery          
  4 times/day   5 drops  1.86 ±   0.94  ±       McCulley
  1 day prior and     0.23    0.15        et al 2006
  1 drop prior to               
  surgery          
  4 drops pre  4 drops  1.55 ±   0.74  ±        Katz et al
  surgery    0.86   0.66       2005
  4 times a day/1  4 drops  1.61 ±   0.91  ±      
  day before and    0.71    0.54       
  4  drops,  pre           
  surgery          
 4  × 2 days pre  8 drops  0.38 ±   0.19  ±       Ong-Tone
  op    0.32   0.23       et  al  2007
 4  × 2 days pre  11  2.16 ±   0.82  ±      
  op plus 3 drops  drops  1.12    0.31       
  2 hours prior to               
  surgery          
 4  × 3 days   12    0.011 ±   0.008  ±      Costello et al
  before  surgery  drops   0.008   0.006     2006
Oral  2 tablets (400 mg)  800 mg    1.55 ±          Fuller et al
  at 14 and 3 hours      0.33          2006
  before  surgery           
  2 tablets, evening  800 mg  1.34 ± 1.58  ±         Hariprasad
  prior to surgery    0.66  0.80          et al 2006
  and  3  hours           
  before  surgery           
  Single tablet   400 mg  0.21 ± 0.09  ±         Vedantham 
  1–2 hours before     0.21  0.09          et al 2005
  surgery          
  Single tablet,   400 mg  2.33 ±         Garcia-
  10 hours before     0.85            Saenz et al
  surgery           2001
  Single dose  400 mg  1.17 ±             Walter et al
  Prior to surgery    0.40 (10             2007
    hours)           
  2 tablets, 12   400 mg  1.23 ±           Kampougeris 
  hours apart    0.55 (12             et al 2007
    hours)           Clinical Ophthalmology 2008:2(1) 85
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and MIC distribution. The third partner in this complex 
relationship is what both the drug and the pathogen do 
to the patient. This interplay is described by the patient’s 
age, genetic background, underlying disease and prior 
antimicrobial exposure.
The ratio of peak concentration (Cmax) to the MIC and the 
area under the concentration curve (AUC) are the pharmaco-
dynamic indices that correlate most favorable with clinical 
outcomes for concentration-dependent anti-infectives. Main-
taining adequate concentration of an antibiotic above a certain 
level known as the mutant prevention concentration (MPC) 
can also reduce the probability of selecting resistant subpopu-
lations and increasing a favorable clinical outcome.
Antibiotic penetration into ocular tissues and ﬂ  uids 
must not only reach but exceed the minimal inhibitory 
concentration (MIC) sufﬁ  ciently to meet the targeted phar-
macodynamic indices (Cmax: MIC or MPC) by a factor of 
10. A Cmax:MIC ratio or MPC values greater than 10 have 
been documented to eradicate pathogens and suppress 
emergence of resistance in patients treated with ﬂ  uoroqui-
nolones (Allen et al 2004; Metzler et al 2004; Smith et al 
2004; Hermsen et al 2005).
Wilhelmus (Wilhelmus 2003; Wilhelmus et al 2003) 
conﬁ  rmed the application and utility of pharmacodynamic 
indices to predict clinical outcome in patients with bacterial 
keratitis. The pharmacodynamic indices (PDI): Cmax:MIC 
and AUC:MIC were use to correlate clinical outcome for 
391 patients with bacterial keratitis. Clinical improvement 
was associated with a Cmax:MIC ratio greater than 8 and an 
AUC:MIC ratio greater than 152. Corneal pathogens included 
S. aureus (21%), P. aeruginosa (12%), S. pneumoniae (7%), 
Streptococcus viridans (5%), other gram-positive isolates 
(44%), and other gram-negative isolates (11%).
Table 6 displays calculated pharmacodynamic indices 
(PDI) for moxiﬂ  oxacin and gatiﬂ  oxacin using reported aque-
ous concentrations and MIC50s/MIC90s values for coagulase 
negative staphylococci recovered from endophthalmitis 
(Mather et al 2002; Miller et al 2006)
Targeted PDIs ranged from less than or equal to 0.038 
μg/mL to 0.228 μg/mL for moxiﬂ  oxacin and less than or 
equal to 0.048–0.094 μg/mL for gatiﬂ  oxacin. Obtainable 
moxiﬂ  oxacin concentrations exceeded the MIC and met 
the PDI factor of 10 for 89% (8/9) and 78% (7/9) of the 
isolates when using the MIC50. None of the moxiﬂ  oxacin 
concentrations were sufﬁ  cient to provide coverage for ﬂ  uo-
roquinolone resistant coagulase negative staphylococci for 
reported MIC90s.
Gatiﬂ  oxacin concentrations met the PDI factor of 10 for 
28% (2/7) of the isolates at the MIC50 value of 0.09 μg/mL. 
None of the obtainable Zymar concentrations met the PDI 
factor of 10 for ﬂ  uoroquinolone resistant isolates at values 
reported by Miller et al (2006).
In a more recent report from the same Institution, Harper 
and colleagues (Harper et al 2007) conﬁ  rmed the low peak 
concentration:mic ratios for both gatiﬂ  oxacin and moxiﬂ  oxa-
cin using reported intraocular levels against 59 coagulase 
negative staphylococci isolates collected between 1993 and 
2006. Moxiﬂ  oxacin ratios (Cmax:MIC90) were higher than 
gatiﬂ  oxacin (0.05 μg/mL vs 0.02 μg/mL) but lower than 
vancomycin (0.45 μg/mL) for reported mean (1.66 μg/mL) 
aqueous concentrations. A signiﬁ  cant difference in the PDI 
parameter was observed for moxiﬂ  oxacin when the MIC50 
Figure 4 Factors affecting favorable outcomes during antimicrobial therapy.
Antimicrobial
Microorganism Patient
Pharmacokinetics
Pathogenicity/virulence
Pharmacodynamics
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rather than the MIC90 was used. The ratio for moxiﬂ  oxacin 
using the MIC50 was 2.2 μg/mL vs 0.83 μg/mL for gatiﬂ  oxa-
cin and 0.67 μg/mL for vancomycin.
Clinical efﬁ  cacy
No clinical trials have been conducted evaluating moxi-
ﬂ  oxacin vs. nonﬂ  uroquinolone antibiotics for the treatment 
of keratitis and or endophthalmitis. In two pre-marketing, 
randomized, double-masked, multi-centered, controlled 
clinical trials to assess, safety and efﬁ  cacy of moxiﬂ  oxacin 
for the treatment of bacterial conjunctivitis, clinical cures 
were documented in 66%–69% of patients by day 4. Micro-
biological eradication occurred in 84%–94% of the patients. 
Patients were dosed 3 times a day for 4 days. Age groups 
ranged from 2 to 92. No adverse events were reported in this 
group (Alfonso and Crider 2005).
Deramo and colleagues reported no signiﬁ  cant difference 
in the rate of endophthalmitis using 4 times a day dosing 
of moxiﬂ  oxacin or gatiﬂ  oxacin pre- and post-operative 
compared to established endophthalmitis infection rates. 
In a retrospective, multicentered review of 20,013 patients 
from 9 cataract centers across 7 states, the overall rate of 
endophthalmitis following cataract surgery was 0.07%. The 
rate of postoperative endophthalmitis in the gatiﬂ  oxacin-
treated group (81%, 16,209) was 0.06% (9 cases) and the 
rate for the moxiﬂ  oxacin-treated group (19%, 3804) was 
0.1% (5 cases). The difference was not signiﬁ  cant (p = 0.11, 
nor was this rate lower than the earlier study by Miller et al 
using clear corneal phacoemulsiﬁ  cation (Miller et al 2005; 
Deramo et al 2006).
Safety and biocompatibility
Reported adverse reactions with 0.5% moxiﬂ  oxacin hydro-
chloride ophthalmic solution administration have included: 
conjunctivitis, keratitis, decreased visual acuity, ocular 
hyperemia, dry eye, itching, subconjunctival hemorrhage, and 
tearing (Alcon Laboratories package insert) (Hariprasad et al 
2005). Other infrequent ocular adverse events reported for the 
ﬂ  uoroquinolones as a class include chemosis, eyelid edema, 
and punctuate epithelial keratitis (Mah 2004).
In vitro and animals studies have demonstrated a concen-
tration dependent toxicity in studies of corneal epithelial cell 
migration and or proliferation, key components in corneal 
wound healing (Mallari et al 2001; Donnenfeld et al 2004; 
Kovoor et al 2004; Burka et al 2005; Durrie and Trattler 
2005; McGee et al 2005; Robertson et al 2005; Solomon 
et al 2005; Donaldson et al 2006; Kaufman et al 2006; Ly 
et al 2006; Matsumoto et al 2006; McDermott and Wheater 
2006; Stern et al 2006; Walter and Tyler 2006).
Matsumoto and colleagues reported low and equivo-
cal cell migration inhibition scores for moxiﬂ  oxacin and 
gatifloxacin versus ciprofloxacin at low concentrations 
Table 6 Comparative MIC50s, MIC90s, and calculated pharmacodynamic indices for moxiﬂ  oxacin and gatiﬂ  oxacin for coagulase-
negative staphylococci versus reported aqueous concentrations
Drug Source  Cmax Calculated    MIC50 MIC50 MIC90
     MIC/MPC
     target  value
        (Mather et al 2002)  (Miller et al 2006)
Moxiﬂ  oxacin  Aqueous  0.38 ± 0.32  0.038  0.05 (FQS) 2.5 (FQR)  0.09  4
   0.88  ± 0.88  0.088    
   1.31  ± 0.46  0.131    
   1.55  ± 0.86  0.155    
   1.61  ± 0.71  0.161    
   1.80  ±1.25  0.180    
   1.86  ± 0.23  0.186    
   2.16  ± 1.12  0.216    
   2.28  ± 1.23  0.228    
Gatiﬂ  oxacin  Aqueous  0.19 ± 0.23  0.019  0.09 (FQS) 2.0 (FQR)  0.19  4
   0.48  ± 0.34  0.048    
   0.63  ± 0.30  0.063    
   0.74  ± 0.66  0.074    
   0.82  ± 0.31  0.082    
   0.91  ± 0.54  0.091    
   0.94  ± 0.15  0.094    
Derived from Mather et al (2002), Miller and Flynn (2006).
Abbreviations: MIC90, concentration that inhibits 90% of isolates tested; MIC50, concentration that inhibits 50% of isolates tested; FQS, ﬂ  uoroquinolone sensitive; FQR, 
ﬂ  uroquinolone resistant.Clinical Ophthalmology 2008:2(1) 87
Moxiﬂ  oxacin hydrochloride ophthalmic solution
(0 .4 mmol/L), but greater toxicity for moxiﬂ  oxacin and 
ciproﬂ  oxacin versus gatiﬂ  oxacin at higher concentrations 
(0.64 mmol/L) (Matsumoto et al 2006).
McDermott and Wheater correlated dilutions and effects 
on migration, adhesion, collagen type four expression and 
presence of ﬁ  bronectin of the two commercially available 
8-methoxy ﬂ  uoroquinolones (moxiﬂ  oxacin and gatiﬂ  oxacin) 
on human corneal and conjunctival epithelial cell lines 
(McDermott and Wheater 2006). Increased toxicity was again 
correlated with higher drug concentrations. Gatiﬂ  oxacin 
was reported to be less toxic than moxifloxacin at all 
concentrations.
Results of other in vitro studies evaluating, the toxicity of 
the 8-methoxyﬂ  uoroquinolones in human and animal corneal 
tissues have been mixed. Stern and colleagues used several 
animal models to compare the cellular effects of gatiﬂ  oxacin 
and moxiﬂ  oxacin on the rate and quality of corneal wound 
healing. In general, they reported greater corneal epithelial 
degradation, greater inhibition of collagen IV synthesis, 
and increased loss of normal structure in the basal lamina 
(Decemet’s membrane) in moxiﬂ  oxacin treated eyes (Stern 
et al 2006).
In two studies from the University of Texas Southwestern 
Medical Center, investigators reported moxifloxacin to 
be less toxic to the corneal epithelium than all currently 
available ophthalmic ﬂ  uoroquinolones (Kovoor et al 2004). 
Confocal assessment documented maintenance of corneal 
epithelial integrity and tight junction organization after short 
term intense dosing with moxiﬂ  oxacin versus gatiﬂ  oxacin. 
Under similar conditions, moxiﬂ  oxacin induced cell loss and 
breakdown of tight junctions (Ly et al 2006).
Outcomes of human studies comparing the biocom-
patibility of moxiﬂ  oxacin with gatiﬂ  oxacin and or older 
ﬂ  uoroquinolones were also mixed. In 14 healthy volunteers, 
where 0.5% moxiﬂ  oxacin and 0.3% gatiﬂ  oxacin drops were 
randomly administered to the right or left eye at 1 minute 
intervals for 5 minutes, higher levels of conjunctival injec-
tion, discomfort and corneal cell drop out per high power 
ﬁ  eld were reported for the moxiﬂ  oxacin eyes than for the 
gatiﬂ  oxacin eyes. No signiﬁ  cant change in pupil size or 
visual acuity was recorded for the two drugs (Kaufman 
et al 2006).
Walter reported two cases of severe corneal toxicity 
after moxiﬂ  oxacin therapy. Both patients were treated for 
persisted sterile corneal ulcers that worsened with intense 
topical dosing with moxiﬂ  oxacin, but resolved after change 
in therapy to corticosteroids and gatiﬂ  oxacin (Walter and 
Tyler 2006).
Donaldson and coworker reported no differences in 
visual acuity, tear breakup time or ocular surface integrity 
in the moxiﬂ  oxacin treated vs. non treated eyes of healthy 
subjects dosed 4 times daily for 3 days. Authors concluded 
that moxiﬂ  oxacin was safe during the 3 day treatment 
period that mimicked a prophylactic dosing regimen for 
patients scheduled for cataract surgery (Donaldson et al 
2006).
Durrie and Trattler compared the safety and toler-
ability of moxiﬂ  oxacin 0.5% ophthalmic solution and 
gatiﬂ  oxacin 0.3% ophthalmic solution for treatment and 
prophylaxis in patients undergoing laser-assisted in situ 
keratomileusis (LASIK) and laser-assisted subepithelial 
keratomileusis (LASEK). No differences between the two 
antibiotics was documented for visual acuity pupil size, 
SSPK, edema, haze, day and night-time glare halos, clarity 
of day or night vision, or dry eye symptoms up to 1 week 
in LASIK patients. Moxiﬂ  oxacin and gatiﬂ  oxacin were 
equivalent in terms of ease of use, speed of recovery, overall 
vision, and overall comfort for this group of patients. No 
differences in corneal healing were observed after LASEK 
surgery (Durrie and Trattler 2005).
Burka et al evaluated the effect of the 8 methoxyﬂ  uo-
roquinolones on epithelial healing following photorefrac-
tive keratectomy (PRK). At one month follow up, the 
moxiﬂ  oxacin treated eyes had smaller defects and healed 
faster than patients treated with gatiﬂ  oxacin (Burka et al 
2005). No signiﬁ  cant differences in visual outcomes were 
found in the six month follow up for these patients (Burka 
et al 2007).
Solomon et al compared penetration and safety of cipro-
ﬂ  oxacin, moxiﬂ  oxacin and gatiﬂ  oxacin in patients scheduled 
for cataract surgery. No clinical evidence of epithelial or 
intraocular toxicity was noted for any of the three drugs 
(Solomon et al 2005).
In general animal, in vitro, and clinical studies indicate the 
ocular and systemic safety and tolerability of moxiﬂ  oxacin 
for the treatment of ocular infections in children (3 days to 
17 years) and adults (up to age 93). Reported adverse events 
including conjunctivitis, keratitis and endophthalmitis have 
been low (McGee et al 2005; Kleinmann et al 2006).
Emerging resistance issues
Greater than 94% of the isolates in the Endophthalmitis 
Vitrectomy Study were gram positive bacteria (Endophthalmitis 
Vitrectomy Study Group 1995; Haimann et al 1996; 
Han et al 1996) . There are increasing reports of gram-
positive pathogens recovered from post refractive surgery Clinical Ophthalmology 2008:2(1) 88
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infections. One of the anticipated advantages of the new 
8-methoxyﬂ  uoroquinolones was the increased activity 
(lower MICs) against resistant gram positive cocci. What 
has emerged among ocular and nonocular comparative 
studies is that the gap in improved coverage for resistant 
gram positive ocular pathogens is less than optimal 
(Kowalski et al 2003; Mather et al 2004; Miller et al 2006; 
Moshirfar et al 2006; Oliveira et al 2007).
Pong et al evaluated the in vitro efﬁ  cacy of moxiﬂ  oxacin 
against clinical isolates with varying degrees of resistance to 
ciproﬂ  oxacin. There was a high correlation between increas-
ing ciproﬂ  oxacin resistant levels and resistant MICs for both 
oﬂ  oxacin and moxiﬂ  oxacin for gram positive isolates. The 
comparative MICs, however, were lower for moxiﬂ  oxacin 
than for oﬂ  oxacin. In general moxiﬂ  oxacin MICs were 8- to 
32-fold lower for gram-positive isolates and up to four fold 
lower for susceptible gram negative isolates than for the older 
ﬂ  uoroquinolones (Pong et al 1999).
The improved activity of moxiﬂ  oxacin and gatiﬂ  oxacin 
against methicillin resistant S. aureus (MRSA) does not 
translated to in vivo efﬁ  cacy. No route of drug administration 
(oral, intravitreal, subconjunctival or topical) has provided 
concentrations that adequately cover the majority of MRSA 
with moderate or high level ciproﬂ  oxacin resistance.
Kotulus and colleagues documented clinical failure in 
a subset of 9 patients with MRSA infections treated with 
moxiﬂ  oxacin or gatiﬂ  oxacin. A third of the patients improved 
with continued treatment with the 8-methoxyﬂ  uoroquinolones; 
however, two thirds needed additional therapeutic intervention 
and only improved when switched to vancomycin and or 
other combination therapy. Patients who failed therapy 
were treated for an average of 4.5 days, while the third with 
favorable outcomes were treated more long term (18.1 days) 
(Kotlus et al 2006). Others have also reported treatment 
failures for patients with MRSA. (Solomon et al 2003; 
Moshirfar et al 2006; Solomon et al 2007; Woodward and 
Randleman 2007).
Coagulase-negative staphylococci remain the most fre-
quent pathogen recovered from post cataract endophthalmitis. 
The consensus is that the origin of pathogens recovered 
from post cataract infections are seeded from the patient’s 
conjunctiva. Small populations of organisms resistant to the 
8 methoxyﬂ  uoroquinolones may be presence as part of the 
resident conjunctiva ﬂ  ora. These may have been “selected” 
following exposure to older ﬂ  uoroquinolone. The high concen-
tration and broad spectrum of the ﬂ  uoroquinolone may disrupt 
normal conjunctival ﬂ  ora and allow for colonization of more 
resistant bacterial and or more nonbacterial pathogens.
Mino de Kaspar and colleagues demonstrated a low rate 
of resistance (2%) among coagulase negative staphylococci 
in their study evaluating the normal conjunctiva ﬂ  ora of 
patients scheduled for anterior segment surgery (Mino de 
Kaspar et al 2005).
Miller et al documented a high level ﬂ  uoroquinolone 
cross resistance among coagulase negative endophthalmitis 
isolates. Increasing resistance to ciproﬂ  oxacin was paral-
leled by increasing resistance to both moxiﬂ  oxacin and 
gatiﬂ  oxacin. Moxiﬂ  oxacin provides coverage for 10/38, 26% 
and gatiﬂ  oxacin 13/38, 66% for the ciproﬂ  oxacin-resistant 
isolates (Miller et al 2006).
Role of moxiﬂ  oxacin in the 
management of ocular bacterial 
infections
No anti-infective provides ideal coverage for all pathogens 
for all infected sites. Selection of an effective anti-infective 
for ophthalmology is dependent on clinical efﬁ  cacy, back-
ground resistance, site of infection, and toxicity.
Moxiﬂ  oxacin hydrochloride ophthalmic solution 0.5% 
is a unique, preservative free, anti-infective which offers 
elevated tissue concentrations, broad spectrum of activity 
and a moderate to high rate of clinical success against com-
mon ocular pathogens. Declining efﬁ  cacy against methicillin 
susceptible and resistant staphylococci and pseudomonas 
species is a concern. Judicious use is warranted to maintain 
utility and reduce selection of resistant populations.
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